Australia's most trusted
source of pharma news
Wednesday, 16 October 2024
Posted 16 October 2024 PM
Sanofi is closer to getting out of the consumer healthcare business, announcing it has entered into negotiations with US-based private equity firm CD&R.
The firm beat out rivals in bidding for the consumer healthcare business, renamed Opella earlier this year, which operates as a standalone company within Sanofi. The deal values Opella at $25.2 billion (15.5 billion euros), according to the Financial Times.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.